Filtros de búsqueda

Lista de obras de

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

artículo científico publicado en 2017

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.

artículo científico publicado en 2008

A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution.

artículo científico publicado en 2005

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2016

A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised

artículo científico publicado en 2004

A gene expression signature for high-risk multiple myeloma.

artículo científico publicado en 2012

A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies.

artículo científico publicado en 2001

A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients

scientific article published on 01 September 1993

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

artículo científico

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

artículo científico publicado en 2009

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

artículo científico publicado en 2007

Absence of intraocular infections after hematopoietic stem cell transplantation at a single center: the experience with current preventive regimens

artículo científico publicado en 2013

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

artículo científico publicado en 2013

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

scientific article published on 08 December 2011

Advances in the treatment of multiple myeloma

artículo científico publicado en 1993

Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.

artículo científico publicado en 2005

Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft

artículo científico publicado en 1994

Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma ⬇️

artículo científico publicado el 15 de noviembre de 1997

Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes

artículo científico publicado en 2014

Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program

artículo científico publicado en 2010

Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas

artículo científico publicado en 2005

Analysis of multidrug‐resistance (MDR‐1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma ⬇️

artículo científico publicado el 1 de enero de 1993

Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.

artículo científico publicado en 2005

Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma

artículo científico publicado en 2003

Anti‐adhesive signals are mediated via major histocompatibility complex class II molecules in normal and neoplastic human B cells: Correlation with B cell differentiation stage ⬇️

artículo científico publicado el 1 de octubre de 1997

Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission ⬇️

artículo científico publicado el 1 de abril de 1992

Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130

artículo científico publicado en 1998

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

artículo científico publicado en 2013

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

artículo científico publicado en 2017

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

artículo científico publicado en 2012

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

artículo científico publicado en 2013

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

artículo científico publicado en 2016

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

artículo científico publicado en 2018

CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma

scientific article published on 01 December 2001

CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease

artículo científico publicado en 1998

CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells

artículo científico publicado en 2002

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

scientific article published on 15 March 2018

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

artículo científico publicado en 2003

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

artículo científico publicado en 1998

Chronic idiopathic axonal polyneuropathy. Comparison of patients with and without monoclonal gammopathy

artículo científico publicado en 1996

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

artículo científico publicado en 2015

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

scientific article published on 23 May 2016

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

artículo científico publicado en 2014

Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells

artículo científico publicado en 2019

Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses

artículo científico publicado en 2016

Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma

artículo científico publicado en 1992

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis

artículo científico publicado en 2008

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group

artículo científico publicado en 2000

Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma

artículo científico publicado en 2001

Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model

artículo científico publicado en 2009

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.

artículo científico publicado en 2017

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

artículo científico publicado en 2001

Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation

artículo científico publicado en 1997

Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy

scientific article published on 01 June 2007

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

artículo científico publicado en 2016

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

artículo científico publicado en 2010

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

artículo científico publicado en 2014

Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67

artículo científico publicado en 1988

Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique

scientific article published on 01 October 1986

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

artículo científico publicado en 2016

Different CD44 splicing patterns define prognostic subgroups in multiple myeloma

artículo científico publicado en 1996

Diffuse large B-cell lymphoma in immunoprivileged sites: association of vitreoretinal, testicular and central nervous system lymphoma

scientific article published on 02 July 2013

Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation ⬇️

artículo científico publicado el 15 de noviembre de 1997

Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells

artículo científico publicado en 1998

Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation

artículo científico publicado en 1999

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

artículo científico publicado en 2000

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study

artículo científico publicado en 2012

Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.

artículo científico publicado en 2006

Drug resistance in multiple myeloma

artículo científico publicado en 1997

Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy

artículo científico publicado en 2012

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial

artículo científico publicado en 2011

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

artículo científico publicado en 2017

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

artículo científico publicado en 2016

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop

artículo científico publicado en 1996

Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen

scientific article published on 09 November 2010

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

artículo científico publicado en 2016

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

artículo científico publicado en 2010

Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement

artículo científico publicado en 2014

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativ

artículo científico publicado en 2015

Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.

artículo científico publicado en 2008

Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment

artículo científico publicado en 2003

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

artículo científico publicado en 2018

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

artículo científico publicado en 2004

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

artículo científico publicado en 2010

Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity

artículo científico publicado en 2003

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

artículo científico publicado en 2011

Geranylgeranylated proteins are involved in the regulation of myeloma cell growth.

artículo científico publicado en 2005

Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma

artículo científico publicado en 2003

Graft-versus-myeloma effect in two cases

scientific article published on 01 March 1996

Growth factors and antiapoptotic signaling pathways in multiple myeloma

artículo científico publicado en 2005

Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years

artículo científico publicado en 2007

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

artículo científico publicado en 2012

High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma

artículo científico publicado en 2007

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

scientific article published on 11 December 2018

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis

artículo científico publicado en 2008

High-risk multiple myeloma treated with high-dose melphalan ⬇️

artículo científico publicado el 1 de enero de 1992

How I treat plasma cell leukemia

artículo científico publicado en 2012

Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells

artículo científico publicado en 2013

Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis

artículo científico publicado en 2005

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines

artículo científico publicado en 1999

Identification of minor histocompatibility antigens based on the 1000 Genomes Project

artículo científico publicado en 2014

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells

artículo científico publicado en 2004

Immune function during ageing in man: relation between serological abnormalities and cellular immune status

artículo científico publicado en 1983

Immune-modulatory effects of bortezomib in GVHD

scientific article published on 01 May 2007

Immunoglobulin gene analysis in polyneuropathy associated with IgM monoclonal gammopathy

scientific article published on 06 March 2006

Immunotherapy in myeloma: how far have we come?

artículo científico publicado en 2019

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

artículo científico publicado en 2018

Impact of ocular graft-versus-host disease on visual quality of life in patients after allogeneic stem cell transplantation: questionnaire study

artículo científico publicado en 2013

Increased plasmin-α2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses

artículo científico publicado en 2007

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma

scientific article published on 01 February 1999

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2018

Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma

scientific article published on 01 February 2007

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

artículo científico publicado en 2003

Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma

artículo científico publicado en 2008

Intensive treatment for multiple myeloma: where do we stand?

artículo científico publicado en 1999

Interleukin-6, a new target for therapy in multiple myeloma?

artículo científico publicado en 1993

Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma

scientific article published on 01 January 1996

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial

scientific article published on 01 July 2007

Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.

artículo científico publicado en 1996

Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.

artículo científico publicado en 2007

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

artículo científico publicado en 2010

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

artículo científico publicado en 2009

J chain disease: an aggressive evolution of multiple myeloma

scientific article published on 01 April 1990

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

artículo científico publicado en 2003

Laryngeal amyloidosis: localized versus systemic disease and update on diagnosis and therapy.

artículo científico publicado en 2004

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma

artículo científico publicado en 2010

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.

artículo científico publicado en 2008

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

artículo científico publicado en 2012

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

artículo científico publicado en 2011

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

artículo científico publicado en 2021

Leptomeningeal metastases from primary plasma cell leukemia

artículo científico publicado en 2013

Localized graft-versus-host disease of the skin provoked by radiotherapy

artículo científico publicado en 2010

Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines

artículo científico publicado en 1998

Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation.

artículo científico publicado en 2004

Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma

artículo científico publicado en 1998

Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma

artículo científico publicado en 1992

MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.

artículo científico publicado en 1994

Malignant transformation in polyneuropathy associated with monoclonal gammopathy

artículo científico publicado en 2005

Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors.

artículo científico publicado en 2001

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

artículo científico publicado en 2010

Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma.

artículo científico publicado en 2009

MicroRNA signatures characterize multiple myeloma patients

artículo científico publicado en 2011

Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives

artículo científico publicado en 2015

Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation

artículo científico publicado en 2008

Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)

artículo científico publicado en 2005

Modulation of chronic excessive interleukin-6 production in multiple mycloma does not affect thyroid hormone concentrations ⬇️

artículo científico publicado el 1 de noviembre de 1997

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

artículo científico publicado el 1 de agosto de 1992

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

artículo científico publicado en 2003

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

artículo científico publicado en 2016

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

artículo científico

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

artículo científico publicado en 2017

Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.

artículo científico publicado en 1998

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

artículo científico publicado en 2017

Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy

scientific article published on 01 December 2006

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

artículo científico publicado en 2013

New developments in the treatment of patients with multiple myeloma

artículo científico publicado en 2010

New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway

artículo científico publicado en 2006

Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern

artículo científico publicado en 1987

Ocular graft-versus-host disease after allogeneic stem cell transplantation

artículo científico publicado en 2010

Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution

artículo científico publicado en 2016

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

artículo científico publicado en 2002

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM

scientific article published on 01 May 2003

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

artículo científico publicado en 2011

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

artículo científico publicado en 2016

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

artículo científico publicado en 2016

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

artículo científico publicado en 2016

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

artículo científico publicado en 2014

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial

scientific article published on 04 April 2019

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

artículo científico publicado en 2015

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

artículo científico publicado en 2010

Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities

artículo científico publicado en 1994

Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy

artículo científico publicado en 2013

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

artículo científico publicado en 2016

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

artículo científico publicado en 2016

Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.

artículo científico publicado en 2018

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

artículo científico publicado en 2014

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

artículo científico publicado en 2015

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2020

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System ⬇️

artículo científico publicado en 2015

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

artículo científico publicado en 2004

Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures

artículo científico publicado en 1994

Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience

artículo científico publicado en 2010

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.

artículo científico publicado en 2006

Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens

artículo científico publicado en 2008

Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells

artículo científico publicado en 2003

Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy

artículo científico publicado en 1997

Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy ⬇️

artículo científico publicado el 1 de julio de 1997

Putative myeloma precursor cells expressing 2,6 sialic acid-modified antigens actually belong to the erythroid lineage

artículo científico publicado en 1998

Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis

artículo científico publicado en 2009

Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.

artículo científico publicado en 2007

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

artículo científico publicado en 2015

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

artículo científico publicado en 2006

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy

artículo científico publicado en 2001

Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.

artículo científico publicado en 2009

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

artículo científico publicado en 2012

Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP ⬇️

artículo científico publicado el 1 de diciembre de 1992

Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma

artículo científico publicado en 2014

Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38- haematopoietic stem cells

artículo científico publicado en 2002

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

artículo científico publicado en 2016

Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced

scientific article published on 01 May 2007

Sporadic late-onset nemaline myopathy effectively treated by melphalan and stem cell transplant

artículo científico publicado en 2008

Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCT.

artículo científico publicado en 2014

Susceptibility of malignant plasma cells to HA-1(H) specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect

artículo científico publicado en 2004

T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells

artículo científico publicado en 2019

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

artículo científico publicado en 2015

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

artículo científico publicado en 2018

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

artículo científico publicado en 2008

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield

artículo científico publicado en 2007

Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%

artículo científico publicado en 2002

The SCID mouse as a model for multiple myeloma

artículo científico publicado en 1995

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

artículo científico publicado en 2002

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

artículo científico publicado en 2014

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

artículo científico publicado en 2003

The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study

artículo científico publicado en 2011

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.

artículo científico publicado en 2015

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

artículo científico publicado en 2004

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

artículo científico publicado en 2011

Therapeutic options in systemic AL amyloidosis

artículo científico publicado en 2004

Three families with polyneuropathy associated with monoclonal gammopathy

artículo científico publicado en 2000

Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis

artículo científico publicado en 2008

Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

artículo científico publicado en 2012

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

artículo científico publicado en 2010

Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH

artículo científico publicado en 2003

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

artículo científico publicado en 2010

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

artículo científico publicado en 2016

Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study

artículo científico publicado en 2015

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

artículo científico publicado en 2015

VAD chemotherapy for refractory multiple myeloma

artículo científico publicado en 1989

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma

artículo científico publicado en 1999

[Clinical judgment and decision making in medical practice. A retiree with fatigue and foot drop]

artículo científico publicado en 1998

[Immune function and aging in man]

scientific article published on 01 October 1983

[Indications for bone marrow biopsy in adults]

scientific article published on 01 February 2005

[Multiple myeloma; treatment in the year 1998]

scientific article published on 01 July 1998

[Pitfalls in the diagnosis and course of Kahler's disease]

artículo científico publicado en 1987

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda